FLSM
XLO icon

Frazier Life Sciences Management’s Xilio Therapeutics XLO Stock Holding History

Frazier Life Sciences Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Sell
422,505
-2
-0% -$16 0.09% 38
2025
Q4 		$3.79M Buy
+422,507
New +$4.44M 0.1% 39

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Frazier Life Sciences Management's XLO Position: Q1 2026 in Review

Frazier Life Sciences Management reduced its Xilio Therapeutics (XLO) stake by 0% in Q1 2026, selling an estimated $16 and leaving 422,505 shares worth $3.55M. The position accounts for 0.09% of the portfolio, ranked #38.

Frazier Life Sciences Management first reported a position in XLO in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.79M in Q4 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Frazier Life Sciences Management held 422,505 shares of Xilio Therapeutics worth $3.55M as of Q1 2026.
  • Frazier Life Sciences Management sold 2 Xilio Therapeutics shares in Q1 2026, an estimated $16.
  • Xilio Therapeutics made up 0.09% of Frazier Life Sciences Management's portfolio in Q1 2026, its #38 holding.
  • Frazier Life Sciences Management first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Frazier Life Sciences Management's Xilio Therapeutics position peaked at $3.79M in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.